CSIMarket
 


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 

Integrated Biopharma Inc's Tangible Leverage Ratio

INBP's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 12.24%, Tangible Leverage Ratio fell to 0.42, below the Integrated Biopharma Inc's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2024, 82 other companies have achieved lower Tangible Leverage Ratio than Integrated Biopharma Inc in the III Quarter 2024. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 80 to 434 .

Explain Tangible Leverage Ratio?
What is INBP Market Share?
What are INBP´s Total Liabilities?


INBP Tangible Leverage Ratio (Mar 31 2024)
III. Quarter
(Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
Y / Y Tangible Equity Change 0.91 % -0.46 % 1.42 % 1.54 % 10.4 %
Y / Y Total Liabilities Change -1.33 % -3.31 % 0.17 % -1.57 % -24.09 %
Tangible Leverage Ratio MRQ 0.42 0.39 0.41 0.35 0.43
INBP's Total Ranking # 434 # 80 # 861 # 838 # 989
Seq. Tangible Equity Change 1.86 % -1.69 % 0.13 % 0.64 % 0.48 %
Seq. Total Liabilities Change 12.24 % -7.75 % 18.05 % -19.28 % 9.99 %



Tangible Leverage Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 83
Healthcare Sector # 168
Overall Market # 434


Tangible Leverage Ratio Statistics
High Average Low
100.15 8.87 0.35
(Sep 30 2018)   (Jun 30 2023)




Financial Statements
Integrated Biopharma Inc's Tangible Equity $ 19 Millions Visit INBP's Balance sheet
Integrated Biopharma Inc's Total Liabilities $ 8 Millions Visit INBP's Balance sheet
Source of INBP's Sales Visit INBP's Sales by Geography


Cumulative Integrated Biopharma Inc's Tangible Leverage Ratio

INBP's Tangible Leverage Ratio for the trailling 12 Months

INBP Tangible Leverage Ratio

(Mar 31 2024)
III. Quarter
(Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
Y / Y Tangible Equity TTM Growth 0.91 % -0.46 % 1.42 % 1.54 % 10.4 %
Y / Y Total Liabilities TTM Growth -1.33 % -3.31 % 0.17 % -1.57 % -24.09 %
Tangible Leverage Ratio TTM 0.39 0.39 0.4 0.4 0.4
Total Ranking TTM # 1 # 7 # 5 # 5 # 5
Seq. Tangible Equity TTM Growth 1.86 % -1.69 % 0.13 % 0.64 % 0.48 %
Seq. Total Liabilities TTM Growth 12.24 % -7.75 % 18.05 % -19.28 % 9.99 %


On the trailing twelve months basis Despite of the net new borrowings of 12.24% during the twelve months period ending in III Quarter 2024 Integrated Biopharma Inc has managed to unchanged Tangible Leverage Ratio in the III Quarter 2024 to 0.39, a new company low.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry INBP recorded the lowest Tangible Leverage Ratio. While Tangible Leverage Ratio total ranking has improved so far to 1, from total ranking in previous 12 month period at 7.

Explain Tangible Leverage Ratio?
What is INBP Market Share?
What are INBP´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Within the Market # 1


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
20.38 3.4 0.39
(Jun 30 2019)   (Mar 31 2024)




Companies with similar Tangible Leverage Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioMar 31 2024 MRQ Total LiabilitiesMar 31 2024 MRQ Tangible Equity
Generation Bio Co   1.17 $ 153.888  Millions$ 131.991  Millions
Arcutis Biotherapeutics Inc   1.16 $ 253.599  Millions$ 218.692  Millions
Liquidia Corporation  1.16 $ 91.421  Millions$ 78.981  Millions
Cervomed Inc   1.00 $ 5.322  Millions$ 5.336  Millions
Arvinas Inc   0.99 $ 602.900  Millions$ 609.700  Millions
Royalty Pharma Plc  0.97 $ 9,539.726  Millions$ 9,863.716  Millions
Cassava Sciences Inc  0.96 $ 75.324  Millions$ 78.482  Millions
Edesa Biotech Inc   0.95 $ 2.093  Millions$ 2.195  Millions
Zyversa Therapeutics Inc   0.93 $ 10.428  Millions$ 11.223  Millions
Entrada Therapeutics Inc   0.90 $ 241.477  Millions$ 269.367  Millions
Supernus Pharmaceuticals inc   0.89 $ 207.698  Millions$ 232.395  Millions
Moleculin Biotech Inc   0.89 $ 9.258  Millions$ 10.439  Millions
Gt Biopharma Inc   0.87 $ 4.600  Millions$ 5.312  Millions
Pds Biotechnology Corp  0.85 $ 31.766  Millions$ 37.183  Millions
Nurix Therapeutics Inc   0.85 $ 143.926  Millions$ 168.748  Millions
Quoin Pharmaceuticals Ltd   0.82 $ 6.998  Millions$ 8.567  Millions
Neurobo Pharmaceuticals Inc   0.75 $ 7.553  Millions$ 10.076  Millions
Lftd Partners Inc   0.73 $ 10.696  Millions$ 14.581  Millions
Dermata Therapeutics Inc   0.72 $ 2.744  Millions$ 3.808  Millions
Beigene Ltd   0.70 $ 2,307.320  Millions$ 3,305.190  Millions
Veru Inc   0.69 $ 26.591  Millions$ 38.331  Millions
Biovie Inc   0.69 $ 12.481  Millions$ 18.115  Millions
Ovid Therapeutics Inc   0.67 $ 52.065  Millions$ 78.279  Millions
Gri Bio Inc   0.64 $ 1.789  Millions$ 2.798  Millions
Anaptysbio inc  0.64 $ 30.485  Millions$ 47.778  Millions
Harmony Biosciences Holdings inc   0.62 $ 239.892  Millions$ 384.247  Millions
Cellectar Biosciences Inc   0.62 $ 16.194  Millions$ 26.166  Millions
Lumos Pharma Inc   0.59 $ 10.346  Millions$ 17.439  Millions
Capricor Therapeutics inc   0.59 $ 10.874  Millions$ 18.435  Millions
Nature s Sunshine Products inc   0.58 $ 93.211  Millions$ 159.707  Millions

Date modified: 2024-05-12T11:59:54+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com